EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST ‐ T1D Extension Study

Eslam Montaser iD, Kanchan Bhasin iD, Davida Kruger, Halis Kaan Akturk iD, Andrew Ahmann iD, Janet K Snell-Bergeon iD, Viral N Shah iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.71287 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Eslam Montaser und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Indiana University School of Medicine, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Blood Glucose, Diabetes Mellitus, Type 1, Hypoglycemic Agents, Insulin. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk, Breakthrough T1D.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To evaluate changes in glycaemic control following semaglutide discontinuation in adults with Type 1 diabetes and obesity who completed the ADJUST‐T1D randomised controlled trial. Materials and Methods Continuous glucose monitoring (CGM) data were collected during a 12‐week extension phase after the ADJUST‐T1D trial. Analyses included participants previously randomised to semaglutide who discontinued treatment ( n = 16) and participants previously randomised to placebo who did not receive a glucagon‐like peptide‐1 receptor agonist during follow‐up ( n = 22). Changes in CGM‐derived metrics from Week 26 to the extension phase were compared using Wilcoxon rank‐sum tests with Benjamini–Hochberg adjustment. Analysis of covariance (ANCOVA) adjusting for Week 26 values was performed as a sensitivity analysis.

Results

Compared with placebo, participants who discontinued semaglutide experienced a greater decline in time in range (70–180 mg/dL) (median change −3.6% vs. 1.5%; adjusted p = 0.044). Semaglutide discontinuation was also associated with greater increases in glucose standard deviation (6.0 vs. 1.2 mg/dL; adjusted p = 0.044) and coefficient of variation (3.1% vs. 1.1%; adjusted p = 0.044), indicating worsening glycaemic variability. Time above range (> 180 mg/dL) increased numerically but did not remain significant after adjustment (adjusted p = 0.064). No significant between‐group differences were observed in hypoglycaemia‐related CGM metrics. ANCOVA analyses showed consistent findings.

Conclusions

In adults with Type 1 diabetes and obesity, semaglutide discontinuation was associated with a greater decline in time in range and increased glycaemic variability compared with placebo over 12 weeks. These findings suggest that glycaemic benefits achieved during treatment may not be fully sustained following withdrawal.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood GlucoseDiabetes Mellitus, Type 1Hypoglycemic AgentsInsulinSemaglutideAdultFemaleHumansMaleMiddle AgedContinuous Glucose MonitoringGlycated HemoglobinGlycemic ControlHypoglycemiaInsulin Infusion SystemsObesityTreatment InterruptionGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

GLP‐1 receptor agonistType 1 diabetesautomated insulin deliverycontinuous glucose monitoringglycaemic variability

Substanzen

Blood GlucoseGlycated HemoglobinHypoglycemic AgentsInsulinSemaglutideGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Division of Endocrinology Diabetes and Metabolism, Henry Ford Hospital, Detroit, Michigan, USA.
  • Barbara Davis Center for Diabetes, University of Colorado, Aurora, Colorado, USA.
  • OHSU Harold Schnitzer Diabetes Health Center, Portland, Oregon, USA.
  • Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, Indiana, USA.

ORCID-Profile: Eslam Montaser, Kanchan Bhasin, Halis Kaan Akturk, Andrew Ahmann, Janet K Snell-Bergeon, Viral N Shah

Förderung

  • Novo Nordisk
  • Breakthrough T1D

Zitieren

APA

Montaser, E., Bhasin, K., Kruger, D., Akturk, H. K., Ahmann, A., Snell-Bergeon, J. K., & Shah, V. N. (2026). Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST ‐ T1D Extension Study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71287

Vancouver

Montaser E, Bhasin K, Kruger D, Akturk HK, Ahmann A, Snell-Bergeon JK, et al. Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST ‐ T1D Extension Study. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71287

BibTeX
@article{Montaser2026,
  author = {Montaser, Eslam and Bhasin, Kanchan and Kruger, Davida and Akturk, Halis Kaan and Ahmann, Andrew and Snell-Bergeon, Janet K and Shah, Viral N},
  title = {Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST ‐ T1D Extension Study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71287}
}
Kostenlos starten →